Endo Health Solutions Inc. / NuPathe Inc.

Acute Migraine in Adults

Disease Overview

Migraine is a disabling neurological disorder affecting roughly 39 million Americans, characterized by severe unilateral throbbing headache often accompanied by nausea, vomiting, and photophobia/phonophobia. Acute therapy historically relied on triptans (5-HT1B/1D agonists) but oral and nasal routes are limited by migraine-associated nausea/vomiting and slow onset. Transdermal and parenteral delivery aim to bypass GI absorption.

Competitive Landscape

At deal time (Dec 2013), the acute migraine market was crowded with seven generic oral triptans (sumatriptan, rizatriptan, zolmitriptan, naratriptan, almotriptan, eletriptan, frovatriptan) plus combination Treximet (sumatriptan/naproxen). Subcutaneous Imitrex/sumatriptan injection and Imitrex/Zomig nasal sprays addressed nausea-related GI absorption issues but injection caused pain and nasal sprays delivered inconsistent dosing. NuPathe's Zecuity was the first and only FDA-approved transdermal migraine patch (approved January 17, 2013) using iontophoresis to deliver sumatriptan through skin, bypassing the GI tract. Endo's $105M-up-front + $116M-CVR offer valued NuPathe at ~$2.85/share with sales-milestone CVR. Teva counter-bid $3.65/share + identical $3.15/share CVR (28% premium upfront), and NuPathe terminated the Endo deal on Jan 21, 2014, paying Endo a $5M break fee. Zecuity launched in September 2015 but was voluntarily withdrawn by Teva in June 2016 after FDA flagged severe burns and permanent scarring at patch sites; FDA approval was formally withdrawn July 2, 2020. The CGRP class (Aimovig 2018+) ultimately reshaped the migraine market the patch had hoped to disrupt.